| Specialty Retail Industry | Consumer Discretionary Sector | Sung-Gu Lee CEO | KRX SM Exchange | KR7003000007 ISIN |
| KR Country | 615 Employees | - Last Dividend | 29 Dec 2020 Last Split | - IPO Date |
Bukwang Pharmaceutical Co., Ltd. stands as a prominent entity in the pharmaceutical sector, possessing a legacy since its inception in 1960. Headquartered in Seoul, South Korea, Bukwang has cemented its reputation domestically and internationally by developing, producing, and marketing a wide array of pharmaceutical products. The company's commitment to enhancing human health and well-being is reflected in its diverse product portfolio that spans across multiple therapeutic areas. With a strong focus on research and development, Bukwang continues to pioneer in unveiling innovative treatments, addressing unmet medical needs in fields such as endocrinology, gastroenterology, cardiology, oncology, and beyond. The dedication to quality and efficacy has propelled Bukwang into a leading position, offering an extensive range of pharmaceutical solutions from ethical drugs to over-the-counter medications and health supplements.